NEW YORK, NY, USA I June 26, 2025 I Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

SEATTLE, WA, USA I June 27, 2025 I Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to ...

TOKYO, Japan I June 27, 2025 I PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting ...

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity ...

SAN FRANCISCO, CA, USA and SUZHOU, China I June 27, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...

ATLANTA, GA, USA I June 27, 2025 I UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of ...

SHANGHAI, China I June 27, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned ...

LEIDEN, The Netherlands & CAMBRIDGE, MA, USA I June 26, 2025 I ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through ...

STUTTGART, Germany I June 27, 2025 I La Merie Publishing announced the release of its newest technology market report about gene therapy technologies for in vivo expression of antibodies. The report ...

SHANGHAI, China I June 25, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes ...

ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends DOYLESTOWN, PA, USA I June 25, 2025 I ​ Metabolics Pharma (“Metabolics”), a privately held, Doylestown-based, ...